September 2019 Volume 15, Issue 9
Volume 15, Issue 9 | September 2019
September 2019
In this Issue
Research & Development
Virtual R&D vs. cancer
Boehringer Ingelheim and MD Anderson form unique R&D center to rapidly advance new cancer treatmentsTARA’s heart-on-a-chip sees success
Heart-on-a-chip system mimics drug response seen in humansThree dimensions of the human genome
New algorithm could enable a closer, more accurate way to model genesMy stars and gar-ters
Genes responsible for regenerating fins in garfish are found to also be present in humansDeepening diversity
NIH-funded research highlights the need for diversity in study populationsAmerican BriVision teams up with BioLite Japan
Collaboration combines early-stage discovery capabilities with clinical trial expertiseDiscovery
New hope for sepsis treatment
UCSD scientists explore the role of PHLPP1 and how its absence can boost survival in miceFrom the uterus to the spine
Amniotic fluid stem cells show promise in models of spina bifidaA break in the case
Two enzymes indicted in inflammation and tumor growth in non-small cell lung carcinomasInsight for research
Company launches first automation-compatible 3D human liver disease platform for NASH drug discoveryProteins and cancer
Eisai enters into collaboration research agreement with University of DundeeClinical Trials
Weaving a Tapestri in oncology
New alliance will use Mission Bio’s Tapestri Platform to investigate Onconova’s rigosertibTaking aim at AML
Chimerix secures license to AML candidate with unique mechanism of actionGenes may regulate immunotherapy
Ziopharm’s Controlled interleukin 12 seems to improve T cell recruitment with less toxicity than past IL-12 therapiesHeart healthy
Combo drug manages cholesterol and CRP in studyGoing up against Prader-Willi
Soleno provides update on ongoing DESTINY PWS Phase 3 trialSpecial Reports
Stem Cells Special Report: Hope over hype
Unveiling the true promise of stem cell therapy, not the empty promisesFeature
Neuroscience 2019 Show Preview: The newest in the neurological
From neurodegenerative disorders to neurogenesis, Neuroscience 2019 showcases cutting-edge researchGuest Commentary: From Prop. 71 to CAR-T and beyond: Enabling another 15 years of patient-centric innovation
In 2004, California voters passed the California Stem Cell Research and Cures Act to create a foundation for regenerative medicine in the United States at a time when federal funding support declined. No one could have predicted the myriad scientific and medical innovations that have arisen since. This commentary takes a look back at what has happened in those 15 years, as well as to the future of the fieldEditor's Focus
Editor’s Focus: Artificial and essential, but still just a tool
Artificial intelligence is an increasingly important component of the life sciences and pharma/biotech, but let's not lose sight of the fact that it should help, not be designed to leadPreclinical
Cancer model metadata
Repositive makes cancer models publicly browsableNew breakthroughs for viral HIV vaccine
HIV-like ‘death star’ strain defeated with gene therapy-inspired approachHigh hopes for HERA
HERA-GITRL shows potent, specific targeting in cancer animal modelsAdjusting alcohol-seeking behavior
Aptinyx presents data demonstrating robust activity of NYX-783 in multiple modelsContract Services
The fruit of a long relationship
Deal takes combined company one step closer toward expanding geographic footprintFurthering formulations
MedPharm expands relationship with Novan on formulation scienceEuropean CMOs invest heavily in containment
Almost 70 percent of CMO high-containment facilities in Europe found in six nationsDiagnostics
TARDIS: A ‘game-changer’
Mayo and TGen join hands with Cambridge on test to improve, personalize breast cancer treatmentA new Alzheimer’s application for LymPro
Todos Medical announces positive Alzheimer’s biomarker clinical data from LymPro TestRevenue on the horizon
CytoDyn inks licensing agreement for PA-14 and PRO 140 for diagnostic useTargeted RNA NGS for breast cancer
Agendia announces publication of study validating use of MammaPrint and BluePrintBusiness & Government Policy
On the cutting edge
A roundup of instrumentation, software and other tools and technology newsIllumina expands genomics accelerator to Cambridge
Company partners with leading European venture capital firms to build genomics startupsNew DNA/RNA therapeutics company goes public
NeuBase Therapeutics closes merger transaction with Ohr PharmaceuticalCRISPR ownership fight gets complicated
Kevin Noonan discusses recent developments around researchers vying for ownership of aspects of the gene-editing technology directed to eukaryotic cellsCommentary
Out of order: Check your ego
Science can continue to humble even the best among us, even when something interesting and practical is discovered
